Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system

Fanny Lemarié, Daniel Croft, Rothwelle Tate, Kevin M. Ryan, Christine Dufès

Research output: Contribution to journalArticle

  • 20 Citations

Abstract

The potential of gene therapy to treat cancer is hampered by the lack of safe and efficacious gene delivery systems able to selectively deliver therapeutic genes to tumors by intravenous administration. With the long-term aim of developing an efficacious cancer-targeted gene medicine, we demonstrated that transferrin-bearing polypropylenimine dendrimer complexed to a plasmid DNA encoding p73 led to an enhanced anti-proliferative activity in vitro, by up to 120-fold in A431 compared to the unmodified dendriplex. In vivo, the intravenous administration of this p73-encoding dendriplex resulted in a rapid and sustained inhibition of tumor growth over one month, with complete tumor suppression for 10 % of A431 and B16-F10 tumors and long-term survival of the animals. The treatment was well tolerated by the animals, with no apparent signs of toxicity. These results suggest that the p73-encoding tumor-targeted polypropylenimine dendrimer should be further explored as a therapeutic strategy for cancer therapy.
LanguageEnglish
Pages2701-2709
Number of pages9
JournalBiomaterials
Volume33
Early online date24 Dec 2011
DOIs
StatePublished - 2012

Fingerprint

Gene Transfer Techniques
Intravenous Administration
Tumors
Genes
Dendrimers
Neoplasms
Animals
Bearings (structural)
Gene therapy
Transferrin
Medicine
Toxicity
Neoplasm Genes
Plasmids
DNA
Therapeutics
Genetic Therapy
Growth

Keywords

  • gene therapy
  • dendrimer
  • DNA
  • nanoparticles
  • tumors
  • gene delivery system

Cite this

@article{75bcc1a07ef547d49ed54bb50eab45ec,
title = "Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system",
abstract = "The potential of gene therapy to treat cancer is hampered by the lack of safe and efficacious gene delivery systems able to selectively deliver therapeutic genes to tumors by intravenous administration. With the long-term aim of developing an efficacious cancer-targeted gene medicine, we demonstrated that transferrin-bearing polypropylenimine dendrimer complexed to a plasmid DNA encoding p73 led to an enhanced anti-proliferative activity in vitro, by up to 120-fold in A431 compared to the unmodified dendriplex. In vivo, the intravenous administration of this p73-encoding dendriplex resulted in a rapid and sustained inhibition of tumor growth over one month, with complete tumor suppression for 10 {\%} of A431 and B16-F10 tumors and long-term survival of the animals. The treatment was well tolerated by the animals, with no apparent signs of toxicity. These results suggest that the p73-encoding tumor-targeted polypropylenimine dendrimer should be further explored as a therapeutic strategy for cancer therapy.",
keywords = "gene therapy, dendrimer, DNA, nanoparticles , tumors, gene delivery system",
author = "Fanny Lemari{\'e} and Daniel Croft and Rothwelle Tate and Ryan, {Kevin M.} and Christine Duf{\`e}s",
year = "2012",
doi = "10.1016/j.biomaterials.2011.12.019",
language = "English",
volume = "33",
pages = "2701--2709",
journal = "Biomaterials",
issn = "0142-9612",

}

Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system. / Lemarié, Fanny; Croft, Daniel; Tate, Rothwelle; Ryan, Kevin M.; Dufès, Christine.

In: Biomaterials, Vol. 33, 2012, p. 2701-2709.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system

AU - Lemarié,Fanny

AU - Croft,Daniel

AU - Tate,Rothwelle

AU - Ryan,Kevin M.

AU - Dufès,Christine

PY - 2012

Y1 - 2012

N2 - The potential of gene therapy to treat cancer is hampered by the lack of safe and efficacious gene delivery systems able to selectively deliver therapeutic genes to tumors by intravenous administration. With the long-term aim of developing an efficacious cancer-targeted gene medicine, we demonstrated that transferrin-bearing polypropylenimine dendrimer complexed to a plasmid DNA encoding p73 led to an enhanced anti-proliferative activity in vitro, by up to 120-fold in A431 compared to the unmodified dendriplex. In vivo, the intravenous administration of this p73-encoding dendriplex resulted in a rapid and sustained inhibition of tumor growth over one month, with complete tumor suppression for 10 % of A431 and B16-F10 tumors and long-term survival of the animals. The treatment was well tolerated by the animals, with no apparent signs of toxicity. These results suggest that the p73-encoding tumor-targeted polypropylenimine dendrimer should be further explored as a therapeutic strategy for cancer therapy.

AB - The potential of gene therapy to treat cancer is hampered by the lack of safe and efficacious gene delivery systems able to selectively deliver therapeutic genes to tumors by intravenous administration. With the long-term aim of developing an efficacious cancer-targeted gene medicine, we demonstrated that transferrin-bearing polypropylenimine dendrimer complexed to a plasmid DNA encoding p73 led to an enhanced anti-proliferative activity in vitro, by up to 120-fold in A431 compared to the unmodified dendriplex. In vivo, the intravenous administration of this p73-encoding dendriplex resulted in a rapid and sustained inhibition of tumor growth over one month, with complete tumor suppression for 10 % of A431 and B16-F10 tumors and long-term survival of the animals. The treatment was well tolerated by the animals, with no apparent signs of toxicity. These results suggest that the p73-encoding tumor-targeted polypropylenimine dendrimer should be further explored as a therapeutic strategy for cancer therapy.

KW - gene therapy

KW - dendrimer

KW - DNA

KW - nanoparticles

KW - tumors

KW - gene delivery system

UR - http://www.scopus.com/inward/record.url?scp=84855966213&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2011.12.019

DO - 10.1016/j.biomaterials.2011.12.019

M3 - Article

VL - 33

SP - 2701

EP - 2709

JO - Biomaterials

T2 - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -